Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Profiling of expression data in melanoma cells with mutant DOT1L, DOT1L inhibitor or shRNA knockdown

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE103081 | GEO | 2018/02/14

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Profiling of expression data in melanoma cells with mutant DOT1L, DOT1L inhibitor or shRNA knockdown

Project description:Profiling of expression data in melanoma cells with mutant DOT1L, DOT1L inhibitor or shRNA knockdown

| PRJNA400162 | ENA

Profiling of expression data in melanoma cells following DOT1L shRNA knockdown

Project description:DOT1L-dependent H3K79 methylation is associated with telomere silencing, meiotic checkpoint control, DNA repair, modulation of constitutive heterochromatin, and transcriptional activation.

2018-02-14 | GSE103080 | GEO

Profiling of expression data in melanoma cells with mutant DOT1L or treated with DOT1L inhibitor

2018-02-14 | GSE103079 | GEO

Gene Expression Profiling of human and mouse melanoma cell lines after shRNA-mediated knockdown of JMJD2C or LSD1

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-12-04 | GSE105166 | GEO

H9-hESC derived human neural stem cells with combinations of mutant IDH1-R132H overexpression, P53 shRNA knockdown and/or ATRX shRNA knockdown

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-11-09 | GSE94962 | GEO

Expression profiling and H3K79me2 ChIP-seq in Prostate cancer cells treated with DOT1L inhibitor

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-08-09 | GSE135575 | GEO

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.

Project description:The KRAS oncogene, present in over 90% of pancreatic ductal adenocarcinomas, is most frequently the result of one of three gain-of-function substitution mutations of codon 12 glycine. Thus far, RAS mutations have been clinically refractory to both direct and selective inhibition by systemic therapeutics. This report presents the results of pre-clinical assessment of a lipoplex comprising a plasmid-encoded, modular bi-functional shRNA (bi-shRNA), which executes selective and multi-mutant allelic KRASG12mut gene silencing, encased within a fusogenic liposome systemic delivery vehicle. Using both a dual luciferase reporter system and a Restriction Fragment Length Polymorphism (RFLP) assay, selective discrimination of KRASG12mut from KRASwt was confirmed in vitro in PANC1 cells. Subsequently, systemic administration of the bi-shRNAKRAS fusogenic lipoplex into female athymic Nu/Nu mice bearing PANC1 xenografts demonstrated intratumoral plasmid delivery, KRASG12mut knockdown, and inhibition of tumor growth, without adverse effect. Clinical trials with the bi-shRNA lipoplex have been implemented.

| S-EPMC5979018 | biostudies-literature

Gene expression changes upon Dot1L knockdown and Dot1L inhibitor treatment during reprogramming

Project description:Through a loss-of-function approach, we identified that inhibition of the histone methyltransferase, Dot1L, accelerated somatic cell reprogramming, significantly increased the yield of induced pluripotent stem (iPS) cell colonies, and substituted for Klf4 and c-Myc in the reprogramming cocktail. To understand the mechanism by which Dot1L inhibition results in these phenotypes, we carried out gene expression profiling using Affymetrix microarrays. GSM723207-GSM723224: Embryonic stem cell-derived fibroblasts (dH1fs) were retrovirally transduced in culture with vectors expressing either a control shRNA or an shRNA targeting Dot1L. These cells were then superinfected with either Oct4, Sox2, Klf4 and c-Myc (OSKM) retroviruses or Oct4, Sox2 and c-Myc (OSM) retroviruses. Total RNA was harvested 6 days later. There were three biologic replicates for each condition. GSM880675-GSM880682: dH1fs were treated with 10uM Dot1L inhibitor (EPZ004777) and then superinfected with Oct4, Sox2, Klf4 and c-Myc (OSKM) retroviruses. Total RNA was harvested 6 days later. There were two biologic replicates for each condition.

2012-03-01 | E-GEOD-29253 | biostudies-arrayexpress

E14 cells knockdown with siRNA or shRNA

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-03-10 | GSE167182 | GEO

shRNA-mediated Myc knockdown and shRNA-mediated knockdown of Myc-induced lncRNA KTN1-AS1 in ST486 Burkitt lymphoma cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-04-03 | GSE119925 | GEO